WELCOME

Dear colleagues,

I would like to take this opportunity to welcome you to the 2nd ERIC Workshop on TP53 Analysis in Chronic Lymphocytic Leukemia which will take place at the Hotel La Palma in Stresa, Italy from 7-8 November 2017.

We hope that you enjoy your stay and that the programme and hands on practical workshop that we have put together fulfill your expectations.

At this Workshop there will be special emphasis on both theoretical and practical aspects of TP53 inactivation in leukemia cells, introduction of TP53 mutational analysis and the clinical diagnostics and data interpretation. We are fortunate to be able to count on the expertise of key professionals in the field. In addition participants will have an opportunity to practice their skills by solving specific tasks with real-life examples during the hands on workshop.

Besides the scientific sessions we would like to invite you to two Social events, allowing us to network in a laid-back and relaxed environment. Further details of these events can be found below.

On behalf of the European Research Initiative on CLL (ERIC) Board and the Organising Committee I would like to thank all participants, invited speakers and chairs for attending this Workshop.

Paolo Ghia
ERIC President

SOCIAL EVENTS

WELCOME DINNER - 6 November 2017
Time and location: 20:00-22:00 at Hotel La Palma (Hotel Restaurant)
Admission: Included in registration. All delegates are welcome to attend.

SOCIAL DINNER - 7 November 2017
Time and location: 20:30-22:30 at Restaurant Casabella, Isola dei Pescatori
Meet up point - Delegates should be at the Hotel hall at 19.30 in order to board the boat and sail to the island.
A lake tour on the way to the restaurant is also included.
Admission: Included in the registration. All delegates are welcome to attend.

Supported with an unrestricted grant by

ERIC
European Research Initiative on CLL

7-8 November 2017
Hotel La Palma, Stresa, Italy
Monday - Nov 6, 2017

20.30 - 22.30 Welcome Dinner - Hotel La Palma (Hotel Restaurant)

Tuesday - Nov 7, 2017

09.00 - 09.30 Registration
09.30 - 09.45 Welcome
Paolo Ghia - Università Vita-Salute San Raffaele, Milan (Italy), Gianluca Gaidano - University of Eastern Piedmont, Novara (Italy), Davide Rossi - Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)

09.45 - 10.00 Key-note lecture
Chairman: Sarka Pospisilova - Masaryk University and University Hospital Brno, Brno (Czech Republic)
Targeting missense and nonsense mutant p53: a novel strategy for cancer therapy
Klas Wiman - Karolinska Institutet, Stockholm (Sweden)

10.00 - 10.45 Session: TP53 defects in CLL
Chairman: Arnon Kater - Academic Medical Center, Amsterdam (The Netherlands)
Clinical importance of TP53 abnormalities in CLL - current status
Gianluca Gaidano - University of Eastern Piedmont, Novara (Italy)
Methodological approaches to detect TP53 mutations - from Sanger to NGS
Richard Rosenquist - Karolinska Institutet, Stockholm (Sweden)
Reporting TP53 gene analysis results in CLL
Eugen Tausch - Ulm University, Ulm (Germany)

10.45 - 11.15 Coffee break

11.15 - 11.45 Session: TP53 defects in CLL
Chairman: Arnon Kater - Academic Medical Center, Amsterdam (The Netherlands)
Clinical importance of TP53 abnormalities in CLL - current status
Gianluca Gaidano - University of Eastern Piedmont, Novara (Italy)
Methodological approaches to detect TP53 mutations - from Sanger to NGS
Richard Rosenquist - Karolinska Institutet, Stockholm (Sweden)
Reporting TP53 gene analysis results in CLL
Eugen Tausch - Ulm University, Ulm (Germany)

11.45 - 12.15 NGS in TP53 mutation analysis - experiences "TP53 subclone identification by CAPP-seq"
Davide Rossi - Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)

12.15 - 13.00 Lunch

13.00 - 14.00 Session: Technical aspects of TP53 mutation analysis
Chairman: Carsten Niemann - Rigshospitalet, Copenhagen (Denmark)
Basic procedures - sampling, material, Sanger sequencing
Sarka Pavlova - Masaryk University and University Hospital Brno, Brno (Czech Republic)
NGS in TP53 mutation analysis - experiences "TP53 mutational profile in CLL: A retrospective study of the FILO group"
Fanny Baran-Marszak - Hôpital Auvergne, Bologna (France)

14.00 - 14.40 NGS in TP53 mutation analysis - experiences "NGS, a suitable approach for TP53 screening in CLL?"
Ferran Nadeu - DIBAPS, Barcelona (Spain)

14.40 - 15.20 NGS in TP53 mutation analysis - experiences "TP53 subclone identification by CAPP-seq"
Davide Rossi - Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)

15.00 - 15.20 NGS in TP53 mutation analysis - experiences "TP53 subclone identification by CAPP-seq"
Davide Rossi - Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)

15.20 - 15.40 CLL targeted NGS gene panel testing: A multi-center comparison
Lesley Ann Sutton - Uppsala University, Uppsala (Sweden)

15.40 - 16.00 Discussion all speakers of the session

16.00 - 16.30 Coffee break

16.30 - 17.00 Glass: a tool for assisted Sanger data analysis
Karol Pal - CEITEC, Masaryk University Brno (Czech Republic)

17.00 - 17.45 Basic bioinformatics - from fastq to variants
Viktor Ljungström - Uppsala University, Uppsala (Sweden)

17.45 - 18.30 Seshat: an innovative tool to handle somatic and germline TP53 variants
Thierry Soussi - Karolinska Institutet, Stockholm (Sweden)

19.30 - 22.30 Social Dinner - Restaurant Casabella, Isola dei Pescatori

Wednesday - Nov 8, 2017

08.30 - 10.30 Practical session: Individual tasks involving Sanger and NGS data analysis, and work with databases. Participants will be split into four groups with assigned tutor.
Personal laptop is required.
Sarka Pavlova, Masaryk University and University Hospital Brno, Brno (Czech Republic) - Group 1
Cristina Tresoldi, Università Vita-salute San Raffaele, Milan (Italy) - Group 2
Evangelia Stalika, CERTH, Thessaloniki (Greece) - Group 3
Alessio Bruscaggin, Oncology Institute of Southern Switzerland, Bellinzona (Switzerland) - Group 4

10.30 - 11.00 Coffee break

11.00 - 11.30 Practical session results
Eugen Tausch - Ulm University, Ulm (Germany)

11.30 - 12.25 Session: Clinical consequences
Chairman: Kostas Stamatopoulos - CERTH, Thessaloniki (Greece)
"TP53 mutations show the way" - discussion of illustrative clinical cases whit televoting system
Kostas Stamatopoulos - CERTH, Thessaloniki (Greece)
Michael Doubek - Masaryk University and University Hospital Brno, Brno (Czech Republic)
David Oscier - Royal Bournemouth Hospital, Bournemouth (United Kingdom)

12.30 - 12.50 Importance of minor TP53 mutated clones in the clinic
Davide Rossi - Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)

12.50 - 13.10 Troubleshooting and "risks" in NGS detection of small subclones
Panagiotis Ballakas - Uppsala University, Uppsala (Sweden)

13.10 - 13.20 Discussion

13.20 - 13.50 TP53 defects in the era of novel agents and mechanisms of resistance beyond TP53
Stephan Stilgenbauer - Ulm University, Ulm (Germany)

13.50 - 14.00 Concluding remarks
Sarka Pospisilova - Masaryk University and University Hospital Brno, Brno (Czech Republic) / Paolo Ghia - Università Vita-salute San Raffaele, Milan (Italy)

14.00 - 15.00 Lunch